Welcome to our dedicated page for Immunoprecise news (Ticker: IPA), a resource for investors and traders seeking the latest updates and insights on Immunoprecise stock.
ImmunoPrecise Antibodies Ltd (IPA) delivers cutting-edge antibody solutions through AI-enhanced multi-omics modeling and proprietary biotechnologies. This news hub provides investors and researchers with essential updates on corporate developments, scientific breakthroughs, and strategic partnerships driving innovation in therapeutic antibody discovery.
Access timely reports on IPA's R&D milestones, regulatory progress, and technology advancements. Our curated collection features press releases covering key areas including patent filings, collaborative research initiatives, and platform enhancements within the antibody development lifecycle.
Stay informed about IPA's role in advancing precision immunology through updates on their custom antibody services, AI-driven discovery platforms, and client-focused solutions for pharmaceutical and academic partners. Bookmark this page for direct access to verified corporate communications and scientific progress reports.
IPA subsidiary BioStrand secures €460,000 grant to enhance its LENSai platform by integrating HYFTs™ with 3D protein structures and functions. This funding, awarded by VLAIO, will support the platform's expansion to improve protein structure predictions, particularly for antibodies and GPCRs. BioStrand aims to provide a comprehensive AI Discovery platform, enhancing data analysis capabilities in biotechnology and precision medicine. Additionally, the company announces the immediate departure of Chief Business Officer Stefan Lang, effective immediately.
IPA announced encouraging results from its PolyTope® TATX-03 antibody cocktail, demonstrating effective neutralization against the Omicron sublineage BA.2. The data showed that the neutralization potency against BA.2 is comparable to BA.1.
All therapeutic antibodies in the cocktail maintained their reactivity to the BA.2 spike protein, reinforcing the product's consistency against SARS-CoV-2 variants.
Dr. Ilse Roodink emphasized the sustained efficacy of TATX-03 against evolving viral mutants, underlining its potential significance in combating COVID-19 variants.
ImmunoPrecise Antibodies has successfully completed its acquisition of BioStrand BV, BioKey BV, and BioClue BV, enhancing its capabilities in bioinformatics and biotechnology. This strategic move, valued at approximately €20 million, aims to leverage AI and machine learning technologies to innovate biotherapeutic discovery processes. The deal includes a combination of common shares and cash, as well as a potential earnout based on BioStrand's future profitability. The integration is expected to significantly improve personalized medicine development.
ImmunoPrecise Antibodies (IPA) has signed a share purchase agreement to acquire BioStrand, BioKey, and BioClue for a total of €20 million, with €2 million in cash and €18 million in equity. This acquisition enhances IPA's capabilities in bioinformatics and biotechnology through its proprietary HYFT patterns, which improve data analysis in multi-omics research. The transaction is expected to attract new clients and support IPA's Talem Therapeutics in antibody development. The deal received unanimous approval and is projected to close by April 15, 2022.
ImmunoPrecise Antibodies Ltd. (IPA) reported its Q3 fiscal 2022 results, achieving project revenue of $4.1 million, a rise of 22.6% year-over-year. Total revenue increased to $4.8 million, up 6.6%. The company invested $1.8 million in R&D, significantly higher than last year. However, it recorded a net loss of $3.8 million, worsening from a $1.3 million loss a year ago. As of January 31, 2022, cash reserves stood at $33.0 million.
IPA and Elektrofi are collaborating to develop a low-volume injectable formulation, TATX-03E, of IPA's COVID-19 antibody cocktail, PolyTope® TATX-03. This self-administered formulation aims to provide a stable and easily distributed option for immunodeficient patients requiring ongoing therapy. The collaboration will utilize Elektrofi's technology to enhance delivery methods, supported by a contract from the Department of Defense. The initiative seeks to establish safety and efficacy through IND-enabling studies, with a focus on meeting patient needs and improving access to critical therapies.
ImmunoPrecise Antibodies (NASDAQ: IPA) has partnered with Elektrofi to develop a low-volume self-injectable formulation of its COVID-19 antibody cocktail, PolyTope® TATX-03, now referred to as TATX-03E. This innovative formulation targets immunocompromised patients who require ongoing treatment, allowing for easier at-home administration. Supported by the Department of Defense's SBIR Program, the collaboration will focus on creating an IND-enabling data package for FDA approval, enhancing access to vital therapies for COVID-19 and similar conditions.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) reports encouraging results from its latest studies on the PolyTope® TATX-03 antibody cocktail for SARS-CoV-2.
- Animal tests show no acute adverse events, indicating a strong safety profile.
- No pharmacokinetic aberrations were observed.
- Maximum tolerated dose studies revealed no toxicity even at 12.5 times the proposed human dose.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) announced a conference call scheduled for March 16, 2022, at 10:30 a.m. ET, to discuss its third quarter fiscal year 2022 financial results and recent business highlights. The company will issue a press release before the call, and management will host a question-and-answer session. Investors can submit their questions to John Mullaly of LifeSci Advisors. The call will be available via webcast and can be accessed from the company's investor relations website.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) announced strong neutralizing data for its PolyTope® TATX-03 antibody cocktail against the SARS-CoV-2 Omicron variant. The company claims TATX-03 is the only first-generation cocktail effective against all tested variants. Following positive in vitro results, IPA plans to submit an Investigational New Drug (IND) application to the FDA. Talem Therapeutics, a subsidiary, filed a patent application for TATX-03, aiming for protection in significant markets. Results indicate potential for broad therapeutic use, even as more variants emerge.
